Compare PGY & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGY | COLL |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | United States | United States |
| Employees | N/A | 357 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | N/A | 2015 |
| Metric | PGY | COLL |
|---|---|---|
| Price | $24.83 | $47.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $39.86 | ★ $45.40 |
| AVG Volume (30 Days) | ★ 4.0M | 589.2K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.63 |
| Revenue | ★ $1,245,946,000.00 | $757,067,000.00 |
| Revenue This Year | $28.75 | $26.35 |
| Revenue Next Year | $17.23 | $3.67 |
| P/E Ratio | ★ N/A | $29.48 |
| Revenue Growth | ★ 28.33 | 26.34 |
| 52 Week Low | $8.27 | $23.23 |
| 52 Week High | $44.99 | $48.37 |
| Indicator | PGY | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 49.27 | 74.26 |
| Support Level | $22.61 | $45.82 |
| Resistance Level | $25.25 | $48.37 |
| Average True Range (ATR) | 1.45 | 1.39 |
| MACD | 0.44 | -0.09 |
| Stochastic Oscillator | 89.92 | 89.52 |
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.